https://www.selleckchem.com/pr....oducts/Cyclopamine.h
onary (15/8%), and hepatic (14.2%) events. Readmission rates are high (29% at 30 days, 49% at 180 days) and 64.2% have to permanently discontinue immune checkpoint inhibitor therapy. Importantly, multiple concurrent toxicities were seen in 21.6% (97/45 of irAE admissions and these patients have a fivefold increased risk of inpatient death.Some older adults cannot meaningfully participate in the testing portion of a neuropsychological evaluation due to significant cognitive impairments. There are limited empirical data on this topi
Like
Comment
Share
